Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCORI To Fund Development Of Data Networks For CER, Clinical Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Patient-Centered Outcomes Research Institute plans up to $68 million in grants to develop two types of national data infrastructure, one aimed at clinical data research networks and the other at patient-powered research networks, that together can help researchers across all spectrums of health care develop robust comparative health care data.

You may also be interested in...

PCORI Approves Drug-Focused Research Grants, Topic For First PCORnet Study

Patient-Centered Outcomes Research Institute board approves a plan for comparative-effectiveness research in a newly formed electronic data network as well as a number of studies tackling drug-related issues.

Big Data Poised To Change Pharma R&D, McKinsey Suggests

A McKinsey & Company white paper highlights the potential for big data gathered from across the health care spectrum to revolutionize pharma R&D.

PatientsLikeMe Developing Platform To Validate Patient-Reported Outcomes

While the primary objective will be to help members of the online patient community better manage their health, the new platform will offer an opportunity for pharmaceutical companies to validate patient-reported outcomes that they develop, something that could be useful as PROs gain more traction in the FDA review process.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts